Avoiding Delays on the Pathway to Clinic
Summary: Time is of the essence in the biopharmaceutical industry. How can developers ensure
they get to the clinic as efficiently and smoothly as possible? Here, Jo Anne Jacobs, Fellow, Drug Product Manufacturing Science and Technology at Catalent Biologics, discus issues that could delay the path to clinic for a biologic and how to avoid them.